Loading quotes...
Forecast
The analysts' average price target is €3.44 (+181.97%). The median is €3.44 (+181.97%).
| Buy |
2 |
| Hold |
0 |
| Sell |
0 |
News Go to news feed
There is currently no news available for this company. We are working on adding more providers to change this.
Financials
| (EUR) | Jun 2026 | |
|---|---|---|
| Revenue | 0 | - |
| Gross profit | 0 | - |
| Net profit | -5.58M | 7.91% |
| EBITDA | -6.46M | 8.20% |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | €105.41M |
Number of shares | 86.24M |
52-week high/low | €1.65 - €0.79 |
| Dividends | No |
Beta | 3.28 |
P/E ratio | -4.06 |
PEG ratio | -0.16 |
P/B ratio | 6.52 |
P/S ratio | 0.00 |
Company profile
Vivani Medical, Inc., ein Unternehmen in der klinischen Phase, entwickelt verschiedene Implantate zur Behandlung chronischer Krankheiten mit hohem ungedecktem medizinischen Bedarf. Das Unternehmen entwickelt ein Portfolio von Miniatur-Arzneimittelimplantaten, die minimal schwankende Arzneimittelprofile liefern, sowie implantierbare Sehprothesen, die blinden Menschen ein nützliches künstliches Sehvermögen verleihen. Der Hauptsitz des Unternehmens befindet sich in Emeryville, Kalifornien.
| Name | VIVANI MEDICAL INC |
| CEO | Adam Mendelsohn |
| Headquarters | Alameda,
ca USA |
| Website | |
| Industry | Health Care Equipment & Supplies |
| IPO | 11/19/2014 |
| Employees | 42 |
Ticker symbols
| Exchange | Symbol |
|---|---|
NASDAQ | VANI |
Frankfurt | U5P.F |
Düsseldorf | U5P.DU |
München | U5P.MU |
Discover assets
Shareholders of VIVANI MEDICAL INC also invest in the following assets
